Six royalty-free voluntary-license partners

Gilead expands voluntary licensing collaborations for once-yearly lenacapavir

Gilead expanded six royalty-free voluntary licensing agreements covering investigational once-yearly lenacapavir for HIV prevention in 120 high-incidence countries, supporting manufacturing readiness, technology transfer and future supply planning.